The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...

Medicxi will use the €500m kitty to continue supporting drug hunters and entrepreneurs in creating asset-focused ...

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...

An update from Genmab ( ($GMAB) ) is now available. On November 10, 2025, Genmab A/S announced a proposed private offering of $1.5 billion in ...

Medicxi has closed a €500M fund, expanded its leadership team and outlined its ongoing work in drug development and company ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market ...

Medicxi Announces €500 Million Fund VNew fund will continue Medicxi’s successful asset-centric company creation and investment strategy. LONDON, UK — November 14, 2025 — Medicxi, a leading European ...

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Reimbursement authority NICE published draft guidance today giving a green light to the use of Columvi (glofitamab) in ...

UK-based life sciences venture capital firm Medicxi today announced the closing of Medicxi V, a 500 million-euros ($579.5 ...

Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $93.86, a -13.30% downside from current levels. In a report released on November 7, Bank of America Securities also ...